Literature DB >> 16929176

Preferential involvement of CX chemokine receptor 4 and CX chemokine ligand 12 in T-cell migration toward melanoma cells.

Tianqian Zhang1, Rajasekharan Somasundaram, Carola Berking, Laura Caputo, Patricia Van Belle, David Elder, Brian Czerniecki, Susan Hotz, Lynn Schuchter, Francis R Spitz, Klara Berencsi, Pyapalli Rani, Francesco Marincola, Ruihua Qiu, Dorothee Herlyn.   

Abstract

Our previous analysis of the role of chemokines in T lymphocyte trafficking toward human tumor cells revealed the migration of a melanoma patient's cytotoxic T lymphocytes (CTL) toward autologous tumor cells, resulting in tumor cell apoptosis, in an organotypic melanoma culture. CTL migration was mediated by CX chemokine receptor (CXCR) 4 expressed by the CTL and CX chemokine ligand (CXCL) 12 secreted by the tumor cells, as evidenced by blockage of CTL migration by antibodies to CXCL12 or CXCR4, high concentrations of CXCL12 or small molecule CXCR4 antagonist. Here, we present the results of T cell migration in one additional melanoma patient and T cell and tumor cell analyses for CXCR4 and CXCL12 expression, respectively, in 12 additional melanoma patients, indicating the preferential role of CXCR4 and CXCL12 in CTL migration toward melanoma cells. These studies add to the increasing body of evidence suggesting that CXCL12 is a potent chemoattractant for T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16929176     DOI: 10.4161/cbt.5.10.3153

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  8 in total

Review 1.  Chemokines and the microenvironment in neuroectodermal tumor-host interaction.

Authors:  Rajasekharan Somasundaram; Dorothee Herlyn
Journal:  Semin Cancer Biol       Date:  2008-11-13       Impact factor: 15.707

Review 2.  The good and the bad of chemokines/chemokine receptors in melanoma.

Authors:  Ann Richmond; Jinming Yang; Yingjun Su
Journal:  Pigment Cell Melanoma Res       Date:  2009-02-14       Impact factor: 4.693

3.  Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma.

Authors:  Jinyan Liu; Feng Li; Yu Ping; Liping Wang; Xinfeng Chen; Dan Wang; Ling Cao; Song Zhao; Bing Li; Pawel Kalinski; Stephen H Thorne; Bin Zhang; Yi Zhang
Journal:  Oncotarget       Date:  2015-09-22

4.  Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy.

Authors:  Tamara García-Salum; Andrea Villablanca; Franziska Matthäus; Andrés Tittarelli; Mauricio Baeza; Cristián Pereda; M Alejandra Gleisner; Fermín E González; Mercedes N López; Jörg D Hoheisel; Johannes Norgauer; Peter J Gebicke-Haerter; Flavio Salazar-Onfray
Journal:  Oncotarget       Date:  2018-03-30

Review 5.  The Ins and Outs of Chemokine-Mediated Immune Cell Trafficking in Skin Cancer.

Authors:  Andrew O Yam; Tatyana Chtanova
Journal:  Front Immunol       Date:  2019-03-07       Impact factor: 7.561

6.  Tumor biology and cancer therapy - an evolving relationship.

Authors:  Thomas Seufferlein; Johann Ahn; Denis Krndija; Ulrike Lother; Guido Adler; Götz von Wichert
Journal:  Cell Commun Signal       Date:  2009-08-13       Impact factor: 5.712

7.  Strategies and challenges in eliciting immunity to melanoma.

Authors:  Andrew R Ferguson; Lisa A Nichols; Angela L Zarling; Elizabeth D Thompson; C Colin Brinkman; Kristian M Hargadon; Timothy N Bullock; Victor H Engelhard
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

8.  CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma.

Authors:  J Y Liu; F Li; L P Wang; X F Chen; D Wang; L Cao; Y Ping; S Zhao; B Li; S H Thorne; B Zhang; P Kalinski; Y Zhang
Journal:  Br J Cancer       Date:  2015-08-18       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.